MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â months

Anna Riccio, Giorgio Walter Canonica(Humanitas University), Alessandra Chiappori(Ospedale Policlinico San Martino), Rossana Rossi(University of Parma), Pierluigi Mauri(Institute of Biomedical Technologies), Louise Benazzi(Institute of Genetic and Biomedical Research), Claudio Micheletto, Roberto W. Dal Negro, Dario Di Silvestre, L. Ferrari
Figshare
January 1, 2017
10.6084/m9.figshare.4742512.v1
Cited by 0

Related Papers

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k